Formulations and related activities for the oral administration of poorly water-soluble compounds in early discovery animal studies: An overview of frequently applied approaches. Part 2

Pharmazeutische Industrie

Volumn 64, Issue 9, 2002, Pages 985-991

  Bittner, Beate ^a   Mountfield, Richard Jolyon ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Bioavailability, oral; Drug discovery; Drug solubility; Exploratory drug formulations; Prodrugs; Salts (of drugs)

Indexed keywords

9,9 BIS(4 FLUOROPHENYL) 3,5 DIHYDROXY 8 (1 METHYL 1H TETRAZOL 5 YL) 6,8 NONADIENOIC ACID; ACETIC ACID; ARGININE; CALCIUM SALT; CHLORIDE; DRUG DERIVATIVE; DRUG VEHICLE; GLYCEROL DERIVATIVE; HALOFANTRINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LY 338522; LYSINE; MAGNESIUM SALT; MESYLIC ACID; METRONIDAZOLE; N,N DIETHYLGLYCINATE ESTER; OLEIC ACID; PHOSPHATE; PIPERAZINE DERIVATIVE; POLYSORBATE 80; POTASSIUM SALT; PRODRUG; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; SODIUM; SUCCINIC ACID; SULFATE; TARTARIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC DERIVATIVE;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG SCREENING; DRUG SOLUBILITY; NONHUMAN; PHARMACODYNAMICS;

EID: 0036396858     PISSN: 0031711X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Panchagnula, R., Thomas, N. S., Biopharmaceutics and pharmacokinetics in drug research, Int. J. Pharm. 201, 131 (2000)
2. Andersen, F. A., Final report on the safety assessment of propylene glycol and polypropylene glycols, J. Am. Coll. Toxicol. 13, 437 (1994)
3. Sweetana, S., Akers, M. J., Solubility principles for parenteral drug dosage form development, PDA J. Pharm. Sci. Technol. 50, 330 (1996)
4. Shah J. C., Chen, J. R., Chow, D., Metastable polymorph of etoposide with higher dissolution rate, Drug Dev. Ind. Pharm. 25, 63 (1999)
5. Li, Z. G., Harlow, R. L., Foris, C. M., et al., Polymorph determination for the GP IIb/IIIa antagonist, roxifiban, using a combination of electron diffraction and synchrotron X-ray powder diffraction techniques, J. Pharm. Sci. 88, 297 (1999)
6. Müller, R. H., Peters, K., Nanosuspensions for the formulation of poorly soluble drugs, I. Preparation by a size-reduction technique, Int. J. Pharm. 160, 229 (1998)
7. Merisko-Liversidge, E., Sarpotdar, P., Bruno, I. et al., Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs, Pharm. Res. 13, 272 (1996)
8. Müller, R. H., Böhm, B. H. L., Grau, M. J., Nanosuspensions: A formulation approach for poorly soluble and poorly bioavailable drugs, in: D. L. Wise (ed.), Handbook of Pharmaceutical Controlled Release Technology, pp. 345-357, Marcel Dekker, New York (2000)
9. Müller, R. H., Jacobs, C., Kayser, O., Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47, 3 (2001)
10. Müller, R. H., Böhm, B. H. L., Nanosuspension, in: R. H. Müller, S. Benita, B. Böhm (eds.), Emulsions and nanosuspensions for the formulation of poorly soluble drugs, pp. 143-147, Medpharm Scientific Publishers, Stuttgart (1998)
11. Liversidge, G. G., Cundy, K. C., Bishop, J. et al., Surface modified drug nanoparticles, US patent No. 5145684 (1991)
12. Müller, R. H., Becker, R., Kruss, B, et al., Pharmaceutical nanosuspensions for medicament administration as system of increased saturation solubility and rate of solution. US patent No.5858410 (1998)
13. Hörter, D., Dressman, J., Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract, Adv. Drug deliv. Rev. 25, 3 (1997)
14. Chaumeil, J. C., Micronization: A method of improving the bioavailability of poorly soluble drugs, Meth. Find. Exp. Clin. Pharmacol. 20, 211 (1998)
15. Phillips, E. M., Byron, P. R., Dalby, R. N., Axial ratio measurements in early detection of crystal growth in suspension-type metered dose inhalers, Pharm. Res. 10, 454 (1993)
16. Zipp, G. L., Rodriguez-Hornedo, N., The mechanism of phenytoin crystal growth, Int. J. Pharm. 98, 189 (1993)
17. Liversidge, G. G., Cundy, K. C., Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs, Int. J. Pharm. 125, 91 (1995)
18. Burcham, D. L., Maurin, M. B., Hausner, E. A. et al., Improved oral bioavailability of the hypercholesterolaemic DMP 565 in dogs following oral dosing in oil and glycol solutions, Biopharm. Drug Dispos. 18, 737 (1997)
19. Löbenberg, R., Amidon, G. L., Modern Bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards, Eur. J. Pharm. Biopharm. 50, 3 (2000)
20. [20 Kubo, H., Mizobe, M., Physicochemical properties of 1-(3, 4-dimethoxyphenyl)-2, 3-bis-(methoxycarbonyl)-4-hydroxy-6, 7, 8-trimethoxynaphthalene, a new hypocholesterolemis agent, and its gastroimestinal absorption in dogs, Yakuzaigaku 55, 244 (1995).
21. Charman, W. N., Stella, V. P., Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules, Int. J. Pharm. 34, 175 (1986)
22. Caliph, S. M., Charman, W. N., Porter, C. J. H., Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymphcannulated and non-cannulated rats, J. Pharm. Sci. 89, 1073 (2000)
23. Yeh, P.-Y., Smith, P. L., Ellens, H., Effect of medium chain glycerides on physiological properties of rabbit intestinal epithelium in vitro, Pharm. Res. 11, 1148 (1994)
24. Humberstone, A. J., Charman, W. N., Lipid-based vehicles for the oral delivery of poorly water-soluble drugs, Adv. Drug Deliv. Rev. 25, 103 (1997)
25. Morehead, W. T., Lewis, R. K., Buehler, I. D., et al., Effect of formulation on the oral bioavailability of DMP 266 in dogs, Pharm. Res. 14, S251 (1997)
26. Aungst, B. J., Nguyen, N. H., Rogers, N. J., et al., Amphiphilic vehicles improve the oral bioavailability of a poorly soluble HIV protease inhibitor at high doses, Int. J. Pharm. 156, 79 (1997)
27. Segura-Bono, M. J., Garrigues, T. M., Merino, V. et al., Compared effects of synthetic and natural bile acid surfactants on xenobiotic absorption. III. Studies with mixed micelles, Int. J. Pharm. 107, 159 (1994)
28. Pithavala, Y. K., Wiedmann, T. S., Zimmerman, C. L., The influence of gut wall metabolism on the intestinal absorption of eretinate from mixed micelles, Pharm. Res. 11, S392 (1994)
29. Taniguchi, K., Muranishi, S., Sezuki, H., Enhanced intestinal permeability to macromolecules, II. Improvement of the large intestinal absorption of heparin by lipid-surfactant mixed micelles in rat, Int. J. Pharm. 4, 219 (1980)
30. Hashida, N., Murakami, M., Yoshikawa, H, et al., Intestinal absorption of carboxyfluorescein entrapped in liposomes in comparison with its administration with lipid-surfactant mixed micelles, J. Pharm. Dyn. 7, 195 (1984)
31. Tokumura, T., Tsushima, Y., Tatsuishi, K, et al., Enhancement of the oral bioavailability of cinnarizine in oleic acid in beagle dogs, J. Pharm. Sci. 76, 286 (1987)
32. Wacher, V. J., Salphati, L., Benet, L. Z., Active secretion and enterocytic drug metabolism barriers to drug absorption, Adv. Drug Del. Rev. 20, 99 (1996)
33. Fromin, M. F., P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs, Int. J. Clin. Pharmacol. Ther. 38, 69 (2000)
34. Batrakova, E. V., Li, S., Miller, D. W. et al., Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and caco-2 cell monolayers, Pharm. Res. 16, 1366 (1999)
35. Dudeja, P. K., Anderson, K. M., Harris, J. S. et al., Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity, Arch. Biochem. Biophys. 319, 309 (1995)
36. Coon, J. S., Knudson, W., Clodfelter, K. et al., Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance, Cancer Res. 51, 897 (1991)
37. Yu, L., Bridgers, A., Polli, J. et al., Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability, Pharm. Res. 16, 1812 (1999)
38. Schunrhuis, G. I., Broxterman, H. J., Pinedo, H. M. et al., The polyoxyethylene castor oil modifies multidrug resistance, Br. J. Cancer 62, 591 (1990)
39. Van Zuylen, L., Verweij, J., Sparreboom, A., Role of formulation vehices in taxane pharmacology, Invest. New Drugs 19, 125 (2001)
40. Mountfield, R., Senepin, S., Schleimer, M, et al., The potential inhibitory effect of formulation ingredients on intesttinal cytochrome P450, Int. J. Pharm. 211, 89 (2000)
41. Bittner, B., Guenzi, A., Fullhardt, P. et al., Improvement of the bioavailability of colhicine in rats by co-administration of D-Tocopherol polycthylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy stearic acid, Arzneim.-Forsch./Drug Res., in press (2002)
42. Constantinides, P. P., Lipid microemulsions for improving drug dissolution and oral absorption: Physical and biopharmaceutical aspects, Pharm. Res. 12, 1561 (1995)
43. Shah, N. H., Carvajal, M. T., Patel, C. I. et al., Self-emulsifying drug delivery systems (SEDDS) with polyglycolized blycerides for improving in vitro dissolution and oral absorption of lipophilic drugs, Int. J. Pharm. 106, 15 (1994)
44. Charman, S. A., Charman, W. N., Rogge, M. C., et al., Self-emalswifying drug delivery systems: Formulation and biopharmaceutic evaluation of an investigational lipophilic compound, Pharm. Res. 9, 87 (1992)
45. Nakanishi, K., Nadai, T., Masada, M, et al., Effect of cyclodextrins on biological membranes. II. Mechanisms of enhancement on the intestinal absorption of non-absorbable drug by cyclodextrins. Chem. Pharm. Bull. 40, 1252 (1992)
46. Pitha, J., Amorphous water soluble derivatives of cyclodextrins: from test tube to patient. J. Controlled Release 6, 309 (1987)
47. Duchene, D., Wouessidjewe, D., Pharmaceutical and medical applications of cyclodextrins, in: S. Dumitrin, (ed.), Polysaccharides in medical applications, pp. 575 602, Marcel Dekker, New York (1996)
48. Loftsson, T., Brewster, M. E., Cyclodextrins as pharmaceutical excipients, Pharm. Technol. Eur. 5, 26 (1997)
49. Irie, T., Uekama, K., Pharmaceutical applications of cyclodextrins, III. Toxicological issues and safety evaluation, J. Pharm. Sci. 86, 147 (1997)
50. Preiss, A., Mehnert, W., Froemming, K.-H., Complexation of hydrocortisone with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin, Arch. Pharm. 327, 729 (1994)
51. Järvinen, T., Järvinen, K., Schwarting, N, et al., β-Cyclodextrin derivatives, SBE4-β-CD and HP-β-CD, increase the oral bioavailability of cinnarizine in beagle dogs. J. Pharm. Sci. 84, 295 (1995)
52. Le Corre, P., Dollo, G., Chevanne, I, et al., Influence of hydroxypropyl-β-cyclodextrin on diphenhydramine intestinal absorption in a rat in situ model, Int. J. Pharm. 169, 221 (1998)
53. Stella, V. J., Rajewsky, R. A., Cyclodextrins: Their future in drug formulation and delivery, Pharm. Res. 14, 556 (1997)
54. Shahrokh, Z., Lee, E., Olivero, A. G. et al., Stability of alkoxycarbonylamidine prodrugs, Pharm. Res. 15, 434 (1998)
55. Nolen III, H., Fedorak, R. N., Friend, D. R., Budenosideβ-D-glucuronide: A potential prodrug for treatment of ulcerative colitis, J. Pharm. Sci. 84, 677 (1995)
56. Stoeckel, K., Hofeinz, W., Lancury, J. P. et al., Stability of cephalosporin prodrug esters in human intestinal juice: Implications for oral bioavailability, Antimicrob. Agents Chemother. 42, 2602 (1998)
57. Krise, J. P., Charman, W. N., Charman, S. A. et al., A novel prodrug approach for tertiary amines. 3 In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs, J. Pharm. Sci. 88, 928 (1999)
58. Ruiz-Balaguer, N., Nacher, A., Casabo, V. G. et al., Non-linear intestinal absorption kinetics of cefuroxime extol in rats, Antimicrob. Agents Chemother, 41, 445 (1997)
59. Shaw, J.-P., Sueoka, C. M., Oliyai, R, et al., Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm. Res. 14, 1824 (1997)
60. Prueksaritannt, T., Gorham, L. M., Breslin, M. I. et al., In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of easter prodrugs of L-767, 679, a potent fibrinogen receptor antagonist. An approach for the selection of a prodrug candidate, Drug Metab. Dispos. 25, 978 (1997)
61. Mahfouz, N. M., Hassan, M. A., Synthesis, chemical and enzymatic hydrolysis, and bioavailability evaluation in rabbits of metronidazole amino acid ester prodrugs with enhanced water solubility, Pharm. Pharmacol. 53, 841 (2001)
62. Ogiso, T., Tanino, T., Kawaratani, D, et al., Enhancement of the oral bioavailability of phenytoin by N-acetylation and absorptive characteristics, Biol. Pharm. Bull. 21, 1084 (1998)
63. Berge, S. M., Bighley, L. D., Monkhonse, D. C., Pharmacentical salts, J. Pharm. Sci. 66, 1 (1977)
64. Gould, P. L., Salt selection for basic drugs, Int. J. Pharm. 33, 201 (1986)
65. Tong, W.-Q., Whitesell, G., In situ salt screening a useful technique for discovery support and preformulation studies, Pharm. Dev. Technol. 3, 215 (1998)
66. Morris, K. R., Fakes, M. G., Thakur, A. B. et al., An integrated approach to the selectio of optimal salt form for a new drug candidate, Int. J. Pharm. 105, 209 (1994)
67. Engel, G. L., Farid, N. A., Faul, M. M. et al., Salt form selection and characterization of LY333531 mesylate monohydrate, Int. J. Pharm. 198, 239 (2000)
68. Porter, C. I. H., Charman, S. A., Humberstone, A. J. et al., Lymphatic transport of halofantrine in the conscious rat when administered as either free base or the hydrochloride salt: Effect of lipid class and lipid vehicle dispersion, J. Pharm. Sci. 85, 357 (1996)